• Image 01
  • Image 02
  • Image 03
  • Image 04
  • Image 05
  • Image 06
Need assistance? Contact Us: 1-800-255-5897

Menu

  • Home
  • About Us
    • Company Overview
    • Management Team
    • Board of Directors
  • Your Loan Service Center
  • MAKE A PAYMENT
  • Business Service Center
  • Contact Us
  • Home
  • About Us
    • Company Overview
    • Management Team
    • Board of Directors
  • Your Loan Service Center
  • MAKE A PAYMENT
  • Business Service Center
  • Contact Us
Recent Quotes
View Full List
My Watchlist
Create Watchlist
Indicators
DJI
Nasdaq Composite
SPX
Gold
Crude Oil
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Vertex Pharmaceuticals (NQ:VRTX)

443.92 UNCHANGED
Streaming Delayed Price Updated: 4:00 PM EDT, Apr 8, 2026 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Press Releases about Vertex Pharmaceuticals

< Previous 1 2 3 4 5 6 7 8 9 Next >
News headline image
Vertex to Announce First Quarter 2026 Financial Results on May 4th
April 06, 2026
From Vertex Pharmaceuticals Incorporated
Via Business Wire
News headline image
Vertex Announces US FDA Approval for Label Extensions of ALYFTREK® and TRIKAFTA®, Expanding Availability of These Medicines to ~95% of All People With CF in the United States
April 01, 2026
From Vertex Pharmaceuticals Incorporated
Via Business Wire
News headline image
New to The Street Announces Broadcast of Show #739 on Bloomberg Television Across the U.S. at 6:30 PM EST
March 21, 2026
Via ACCESS Newswire
News headline image
Vertex Announces Positive Week 36 Interim Analysis Results for Primary and All Secondary Endpoints in the RAINIER Phase 3 Trial of Povetacicept in Adults With IgA Nephropathy
March 09, 2026
From Vertex Pharmaceuticals Incorporated
Via Business Wire
News headline image
Vertex to Participate in Upcoming March Investor Conferences
March 05, 2026
From Vertex Pharmaceuticals Incorporated
Via Business Wire
News headline image
Vertex to Present New Data on JOURNAVX® That Demonstrates Effective Pain Management Following Aesthetic and Reconstructive Procedures
March 05, 2026
From Vertex Pharmaceuticals Incorporated
Via Business Wire
News headline image
Vertex to Participate in TD Cowen 46th Annual Health Care Conference on March 3
February 17, 2026
From Vertex Pharmaceuticals Incorporated
Via Business Wire
News headline image
Vertex Reports Fourth Quarter and Full Year 2025 Financial Results
February 12, 2026
From Vertex Pharmaceuticals Incorporated
Via Business Wire
News headline image
Breaking Barriers: How 2026’s Top Clinical Leaders Are Disrupting Chronic Disease Markets
January 23, 2026
Issued on behalf of Avant Technologies Inc. 
From Equity Insider
Via GlobeNewswire
News headline image
Vertex to Announce Fourth Quarter and Full Year 2025 Financial Results on February 12th
January 20, 2026
From Vertex Pharmaceuticals Incorporated
Via Business Wire
News headline image
Vertex Provides Pipeline and Business Updates in Advance of Upcoming Investor Meetings
January 11, 2026
From Vertex Pharmaceuticals Incorporated
Via Business Wire
News headline image
Vertex to Present at the 44th Annual J.P. Morgan Healthcare Conference on January 12
December 22, 2025
From Vertex Pharmaceuticals Incorporated
Via Business Wire
News headline image
From Insulin Injections to Functional Cures: Regenerative Medicine Reshapes Diabetes
December 16, 2025
Issued on behalf of Avant Technologies Inc. 
From USA News Group
Via GlobeNewswire
News headline image
Vertex Presents New Data on CASGEVY®, Including First-Ever Data in Children Ages 5-11 Years, at the American Society of Hematology Annual Meeting and Announces Plan for Global Regulatory Submissions
December 06, 2025
From Vertex Pharmaceuticals Incorporated
Via Business Wire
News headline image
Vertex to Participate in the Citi’s 2025 Global Healthcare Conference on December 3
November 19, 2025
From Vertex Pharmaceuticals Incorporated
Via Business Wire
News headline image
Vertex Presents Updated Phase 1/2 Data From RUBY-3 Study That Continue to Demonstrate Best-in-Class Potential for Povetacicept in Adults with IgA Nephropathy and Primary Membranous Nephropathy at American Society of Nephrology Kidney Week
November 08, 2025
From Vertex Pharmaceuticals Incorporated
Via Business Wire
News headline image
Vertex Reports Third Quarter 2025 Financial Results
November 03, 2025
From Vertex Pharmaceuticals Incorporated
Via Business Wire
News headline image
Vertex to Participate in the UBS Global Healthcare Conference on November 11
October 27, 2025
From Vertex Pharmaceuticals Incorporated
Via Business Wire
News headline image
Vertex Presents New Data Across Portfolio of Cystic Fibrosis Medicines Including ALYFTREK® at the North American Cystic Fibrosis Conference
October 23, 2025
From Vertex Pharmaceuticals Incorporated
Via Business Wire
News headline image
Vertex Announces Progress in Povetacicept Development Program and Presentation of New Data at American Society of Nephrology Kidney Week
October 17, 2025
From Vertex Pharmaceuticals Incorporated
Via Business Wire
News headline image
Vertex to Announce Third Quarter 2025 Financial Results on November 3rd
October 06, 2025
From Vertex Pharmaceuticals Incorporated
Via Business Wire
News headline image
Vertex Announces Key Advancements Across Kidney Portfolio
September 25, 2025
From Vertex Pharmaceuticals Incorporated
Via Business Wire
News headline image
Vertex Partners with Basketball World Champion Jayson Tatum to Raise Awareness of JOURNAVX®, a Non-Opioid Medicine Approved for the Treatment of Moderate-to-Severe-Acute Pain
September 23, 2025
From Vertex Pharmaceuticals Incorporated
Via Business Wire
News headline image
Vertex Announces CASGEVY® Reimbursement Agreement for the Treatment of Transfusion-Dependent Beta Thalassemia and Sickle Cell Disease in Italy
September 18, 2025
From Vertex Pharmaceuticals
Via Business Wire
News headline image
Vertex Scientists Awarded the 2025 Lasker~DeBakey Clinical Medical Research Award for Pioneering Discoveries in Cystic Fibrosis
September 11, 2025
From Vertex Pharmaceuticals Incorporated
Via Business Wire
News headline image
Vertex to Participate in Upcoming September Investor Conferences
August 20, 2025
From Vertex Pharmaceuticals Incorporated
Via Business Wire
News headline image
Vertex Reports Second Quarter 2025 Financial Results
August 04, 2025
From Vertex Pharmaceuticals Incorporated
Via Business Wire
News headline image
Vertex Announces Results from Phase 2 Study of VX-993 for the Treatment of Acute Pain
August 04, 2025
From Vertex Pharmaceuticals Incorporated
Via Business Wire
News headline image
Vertex Named a Premier, Inc. Breakthroughs Innovation Celebration Winner for JOURNAVX™, a First-in-Class Non-Opioid Treatment for Adults With Moderate-to-Severe Acute Pain
July 14, 2025
From Vertex Pharmaceuticals Incorporated
Via Business Wire
Breaking Through: Systemic Genetic Medicines for Hard-to-Treat Cancers
July 09, 2025
Via Investor Brand Network
< Previous 1 2 3 4 5 6 7 8 9 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.

Having difficulty making your payments? We're here to help! Call 1-800-255-5897

Copyright © 2019 Franklin Credit Management Corporation
All Rights Reserved
Contact Us | Privacy Policy | Terms of Use | Sitemap